First Choice Healthcare Solutions (FCHS) 10-Q 8 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 04, 2018
Document And Entity Information
Entity Registrant Name	First Choice Healthcare Solutions, Inc.
Entity Central Index Key	1,416,876
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		32,547,189
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,018

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets
Cash (amounts related to VIE of $478,740 and $702,476)	$ 8,474,437	$ 2,015,534
Accounts receivable, net (amounts related to VIE of $4,129,865 and $4,420,605)	9,908,563	8,699,714
Employee loans (amounts related to VIE of $490,250 and $490,550)	1,268,487	1,155,109
Prepaid and other current assets (amounts related to VIE of $235,707 and $425,725)	630,285	676,931
Total current assets	20,281,772	12,547,288
Property, plant and equipment, net (amounts related to VIE of $209,950 and $469,927)	2,519,638	2,295,163
Other assets (amount relating to VIE $22,005 and $921,470)	3,824,483	3,908,781
Total assets	26,625,893	18,751,232
Current liabilities
Accounts payable and accrued expenses (amounts related to VIE of $854,018 and $1,479,075)	2,545,295	2,379,404
Accounts payable, related party (amount related to VIE of $0 and $251,588)	251,588	251,588
Tax Payable	230,037	223,899
Line of credit, short term (amount related to VIE of $440,024)	440,024	440,024
Notes payable, current portion (amount related to VIE of $24,975 and $0)	49,515	29,552
Unearned revenue	44,557	44,607
Deferred rent, short term portion (amount related to VIE of $27,142 and $45,203)	81,410	105,171
Total current liabilities	3,642,426	3,474,245
Long term liabilities:
Deposits held	41,930	41,930
Line of credit, long term	1,100,000	1,100,000
Notes payable, long term portion (amount related to VIE of $95,734 and $0)	149,288	60,146
Deferred rent, long term portion (amount related to VIE of $1,975,808 and $2,510,406)	2,641,579	2,589,568
Total long term liabilities	3,932,797	3,791,644
Total liabilities	7,575,223	7,265,889
Temporary equity-2022 Put Option	7,500,000
Equity
Preferred stock, $0.01 par value; 1,000,000 shares authorized, Nil issued and outstanding
Common stock, $0.001 par value; 100,000,000 shares authorized, 32,172,389 and 27,356,838 shares issued; 32,172,389 and 27,167,818 shares outstanding as of March 31, 2018 and December 31, 2017, respectively	32,172	27,357
Additional paid in capital	24,982,457	25,185,487
Treasury stock, 0 and 189,020 common shares, at cost, respectively		(249,265)
Accumulated deficit	(13,709,680)	(13,989,018)
Total stockholders' equity attributable to First Choice Healthcare Solutions, Inc.	11,304,949	10,974,561
Non-controlling interest (note 10)	245,721	510,782
Total equity	11,550,670	11,485,343
Total liabilities and equity	$ 26,625,893	$ 18,751,232

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Prepaid and other current assets	$ 630,285	$ 676,931
Property, plant and equipment, net of accumulated depreciation	1,640,400	1,165,219
Other assets	3,824,483	3,908,781
Accounts payable and accrued expenses	2,545,295	2,379,404
Accounts payable, related party	251,588	251,588
Line of credit, short term	440,024	440,024
Notes payable, current portion	49,515	29,552
Deferred rent, short term portion	81,410	105,171
Notes payable, long term portion	149,288	60,146
Deferred rent, long term portion	$ 2,641,579	$ 2,589,568
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	32,172,389	27,356,838
Common stock, shares outstanding	32,172,389	27,167,818
Treasury stock	0	189,020
VIE [Member]
Cash Related to VIE	$ 478,740	$ 702,476
Accounts receivable	4,129,865	4,420,605
Employee loans	490,250	490,550
Prepaid and other current assets	235,707	425,725
Property, plant and equipment, net of accumulated depreciation	209,950	469,927
Other assets	22,005	921,470
Accounts payable and accrued expenses	854,018	1,479,075
Accounts payable, related party	0	251,588
Line of credit, short term	440,024
Notes payable, current portion	24,975	0
Deferred rent, short term portion	27,142	45,203
Notes payable, long term portion	95,734	0
Deferred rent, long term portion	$ 1,975,808	$ 510,406

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Patient service revenue	$ 8,481,672	$ 7,406,986
Allowance for bad debts	(278,562)	(264,996)
Net patient service revenue	8,203,110	7,141,990
Rental revenue	582,787	578,363
Total revenue	8,785,897	7,720,353
Operating expenses:
Salaries and benefits	4,329,285	3,716,375
Other operating expenses	2,632,786	2,529,183
General and administrative	1,353,836	1,173,834
Depreciation and amortization	201,912	189,488
Total operating expenses	8,517,819	7,608,880
Net income from operations	268,078	111,473
Other income (expense):
Miscellaneous income	40,322	50,102
Interest expense, net	(23,512)	(32,074)
Total other income	16,810	18,028
Net income before provision for income taxes	284,888	129,501
Income taxes (benefit)
Net income	284,888	129,501
Non-controlling interest (note 10)	(5,550)	73,018
NET INCOME ATTRIBUTABLE TO FIRST CHOICE HEALTHCARE SOLUTIONS, INC.	$ 279,338	$ 202,519
Net income per common share, basic	$ 0.01	$ 0.01
Net income per common share, diluted	$ 0.01	$ 0.01
Weighted average number of common shares outstanding, basic	28,610,793	26,252,505
Weighted average number of common shares outstanding, diluted	29,410,793	27,052,505

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($)	Common Stock	Additional Paid-In Capital	Treasury Stock	ReAccumulated Deficit	Noncontrolling Interest	Total
Beginning Balance, Amount at Dec. 31, 2017	$ 27,357	$ 25,185,487	$ (249,265)	$ (13,989,018)	$ 510,782	$ 11,485,343
Beginning Balance, Shares at Dec. 31, 2017	27,356,838		189,020
Common stock previously issued returned to treasury, Amount	$ (5)	5
Common stock previously issued returned to treasury, Shares	(5,000)
Common stock issued for services rendered, Amount	$ 9	13,566				$ 13,575
Common stock issued for services rendered, Shares	9,571					9,571
Common stock previously issued returned to treasury and canceled, Amount	$ (189)	$ (249,076)	$ 249,265
Common stock previously issued returned to treasury and canceled, Shares	(189,020)		(189,020)
Sale of common sock, Amount	$ 5,000,000
Sale of common sock,Shares	5,000	7,495,000				7,500,000
Reclassify put option in connection to sale of common stock to temporary equity		$ (7,500,000)				$ (7,500,000)
Acquisition of Crane Creek Surgery Center		(129,389)			(270,611)	(400,000)
Stock based compensation , Amount		166,864				166,864
Net income				279,338	5,550	284,888
Ending Balance, Amount at Mar. 31, 2018	$ 32,172	$ 24,982,457		$ (13,709,680)	$ 245,721	$ 11,550,670
Ending Balance, Shares at Mar. 31, 2018	32,172,389

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income	$ 284,888	$ 129,501
Adjustments to reconcile net income to cash used in operating activities:
Depreciation and amortization	201,912	189,488
Allowances for bad debts	278,562	264,996
Stock based compensation	180,439	63,324
Changes in operating assets and liabilities:
Accounts receivable	(1,487,411)	(1,118,306)
Prepaid expenses and other current assets	46,646	(229,258)
Employee loans	(113,378)	(132,791)
Accounts payable and accrued expenses	165,891	353,849
Deferred rent	28,250	51,871
Unearned income	(50)	16,918
Net cash used in operating activities	(414,251)	(410,408)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of Crane Creek Surgical Center	(400,000)
Purchase of equipment	(335,951)	(173,729)
Net cash (used in) provided by investing activities	(735,951)	(173,729)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	7,500,000
Proceeds from notes payable	120,709	22,113
Payments on notes payable	(11,604)	(130,125)
Net cash provided by (used in) financing activities	7,609,105	(108,012)
Net increase (decrease) in cash and cash equivalents	6,458,903	(692,149)
Cash and cash equivalents, beginning of period	2,015,534	4,593,638
Cash and cash equivalents, end of period	8,474,437	3,901,489
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for interest	23,629	32,328
Cash paid during the period for taxes

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2018
Basis Of Presentation
BASIS OF PRESENTATION	NOTE 1 — BASIS OF PRESENTATION First Choice Healthcare Solutions, Inc. (“FCHS,” “the Company,” “we,” “our” or “us”) is actively engaged in implementing a defined growth strategy aimed at building a network of localized, integrated healthcare services platforms comprised of non-physician-owned medical centers of excellence, which concentrate on treating patients in the following specialties: Orthopaedics, Spine Surgery, Interventional Pain Medicine and related diagnostic and ancillary services in key high growth markets. The unaudited condensed consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries: First Choice Medical Group of Brevard LLC, Marina Towers, LLC, FCID Medical Inc., TBC Holdings of Melbourne, Inc., CCSC Holdings, Inc. and Crane Creek Surgical Partners, LLC., along with the VIE, The B.A.C.K. Center. All significant intercompany balances and transactions, including those involving the VIE, have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of March 31, 2018 and for the three months ended March 31, 2018 and 2017. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the operating results for the full year ending December 31, 2018 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2017 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on April 2, 2018.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2018
Significant Accounting Policies
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of the financial statements in conformity with United States generally accepted accounting principles (“U. S. GAAP”) requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates include the recoverability and useful lives of long-lived assets, provision against bad debt, the fair value of the Company’s stock, and stock-based compensation. Actual results may differ from these estimates. Revenue recognition The Company recognizes revenue when: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company recognizes, significant patient service revenue at the time the services are rendered, even though it does not assess the patient’s ability to pay. Therefore, The Company’s interim and annual periods reports disclose both, its policy for assessing and disclosing the timing and amount of uncollectable patient service revenue recognized as doubtful. Qualitative and quantitative information about significant changes in the allowance for doubtful accounts related to patient accounts receivable are disclosed in the Company’s reports. These estimates are based upon the history and identified trends for each of our payers. Patient fee revenue Patient fee revenue, net of contractual allowance and discounts, consists of net patient fees received from insurance companies, third party payors (including federal and state agencies), hospitals and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments and discounts. Patient fee revenue is recorded in the period in which the services are provided Rental Revenue In addition to housing our corporate headquarters and First Choice Medical Group, the building leases 38,334 square feet of commercial office space to non-affiliated tenants. Our corporate headquarters and FCID Holdings offices currently utilize 4,274 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 21,902 square feet on the ground, first and second floors. Concentrations of credit risk The Company’s financial instruments that are exposed to a concentration of customer risk and accounts receivable risk. Occasionally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. Revenues and accounts receivable are concentrated between two major payers with the approximate risk level outlined below. Concentration of Risk Revenue Concentration: Three months ended March 31, 2018 2017 Medicare 36.0 % 35.5 % Commercial Payor 1 15.9 % 19.0 % Commercial Payor 2 — 11.0 % Receivable Concentration: March 31, March 31, 2018 2017 Medicare 24.6 % 22.9 % Commercial Payor 1 11.6 % 17.4 % Commercial Payor 2 11.9 % 11.7 % Accounts receivables Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the allowance for doubtful accounts. Patient receivables: Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides an allowance for doubtful accounts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts. Rental receivables: Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful accounts. In the year ended 2017, the Company changed its estimates of the allowance for doubtful accounts related to its customers, primarily based on historical experience of write-offs of outstanding accounts receivable. The result of this change in estimate resulted in an increase compared to the year ended December 31, 2016 to the allowance for doubtful accounts by approximately $3.2 million in the year ended 2017. As of March 31, 2018, and December 31, 2017, the Company’s allowance for doubtful accounts was $7,563,566 and $7,285,004 respectively. Net (loss) income per share Basic net (loss) income per common share is based upon the weighted-average number of common shares outstanding. Diluted net income per common share is based on the weighted-average number of common shares outstanding and potentially dilutive common shares outstanding and computed as follows: Three Months ended March 31, 2018 2017 Numerator: Net income attributable to First Choice Healthcare Solutions, Inc. $ 279,338 $ 202,519 Denominator: Weighted-average common shares, basic 28,610,793 26,252,505 Weighted-average common shares, diluted 29,410,793 27,052,505 Basic: $ 0.01 $ 0.01 Diluted: $ 0.01 $ 0.01 Potentially dilutive common shares from convertible debt, options and warrants are determined by applying the treasury stock method to the assumed exercise of warrants and share options are were excluded from the computation of the diluted net income per share because their inclusion would be anti-dilutive. In addition, there were no vested restrict stock for periods presented. Potentially dilutive securities excluded from the basic and diluted net income per share are as follows: March 31, 2018 2017 Warrants to purchase common stock 1,875,000 1,875,000 Options to purchase common stock 3,000,000 3,000,000 Restricted stock awards 1,248,777 660,000 Total 6,123,777 5,535,000 Stock-based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the unaudited condensed consolidated statements of operations, as if such amounts were paid in cash. Upon exercise of a common stock equivalent, the Company issues new shares of common stock out of its authorized shares. Segment information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all the material financial information related to the Company’s principal operating segments. (See Note 11 – Segment Reporting). Treasury Stock The Company uses the cost method when it purchases its own common stock as treasury shares and displays treasury stock as a reduction of shareholders’ equity. As of March 31, 2018 the Company canceled all of its outstanding treasury stock. Reclassifications Certain reclassifications have been made to prior period’s data to conform to the current year’s presentation. These reclassifications had no impact on reported income. Litigations, Claims and Assessments From time to time, we may become involved in lawsuits and legal proceedings which arise in the ordinary course of business including potential disputes with patients. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our physicians. Currently, we have no pending litigation that is deemed to be material to the consolidated financial statements. Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers” to supersede previous revenue recognition guidance under current U.S. GAAP. The guidance presents a single five-step model for comprehensive revenue recognition that requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Two options are available for implementation of the standard which is either the retrospective approach or cumulative effect adjustment approach. The guidance becomes effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. The Company adopted ASU 2014-09 using the modified retrospective transition method in the first quarter of 2018 and such adoption did not have a material impact on the condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases except for short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its financial statements and related disclosures. In August 2016, the FASB issued ASU 2016-15—Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2016-15 in the first quarter of 2018 and such adoption did not have a material impact on the Company. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company adopted ASU 2017-01 in the first quarter of 2018 and such adoption did not have a material impact on the Company. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value because of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently reviewing the impact of adoption of ASU 2017-11 on its financial statements. Subsequent events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

LIQUIDITY

LIQUIDITY	3 Months Ended
	Mar. 31, 2018
Liquidity Disclosures [Abstract]
LIQUIDITY	NOTE 3 – LIQUIDITY The Company incurred various non-recurring expenses in 2017 in connection with the planned development of its Healthcare Services Business. Management believes continued growth in 2018 will support improved liquidity. On March 1, 2018 the Company received $7.5 million in cash in exchange for issuing five million shares of common stock. The Company believes that the current cash balance and line of credit (see notes), along with continued execution of its business development plan, will allow the Company to further improve its working capital; and currently anticipates that it will have sufficient capital resources to meet projected cash flow requirements through the date at least one year from the filing of this report. However, to execute the Company’s business development plan, which there can be no assurance we will achieve, the Company may need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means and potentially reduce operating expenditures. If the Company is unable to secure additional capital, it may be required to curtail its business development initiatives and take additional measures to reduce costs to conserve its cash.

LINES OF CREDIT

LINES OF CREDIT	3 Months Ended
	Mar. 31, 2018
Line of Credit Facility [Abstract]
LINES OF CREDIT	NOTE 4 — LINES OF CREDIT Line of credit, CT Capital FCMG - Brevard entered into a Loan and Security Agreement (the “Loan Agreement”) with CT Capital, Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership (the “Lender”). Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of $2,500,000 to FCMG - Brevard with an interest rate of 6% per annum (the “Loan”). Interest is due and payable monthly. The Lender may convert up to $2,000,000 of the outstanding principal amount or interest on the Loan into common stock of the Company at a conversion price of $0.75 per share. On December 27, 2017, the Loan Agreement with CT Capital, Ltd. (“Lender”) was amended to extend the Maturity Date to December 31, 2019 and further provide that neither the Company nor Lender shall effectuate any conversion of the Loan to the extent that after giving effect to any such conversion, the Lender would beneficially own in excess of 9.99% of the number of shares of our Company’s shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of the Loan by the Lender. The obligations of the Company under the Loan Agreement, as amended, are guaranteed by certain affiliates of the Company, including a personal guarantee issued by the Company’s Chief Executive Officer. As of March 31, 2018, and December 31, 2017, the outstanding balance was $1,100,000 and the remaining principal amount the Lender can convert into common stock is $600,000, subject to the limitations set forth above. The balance available on the line of credit is $1,400,000 as of March 31, 2018. Line of credit, Florida Business Bank The B.A.C.K. Center is a party to a Promissory Note with Florida Business Bank, a Florida banking corporation. Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of $1,383,000 (as amended), with an interest rate of Prime floating plus 1.0%, as published in The Wall Street Journal Interest shall be due and payable monthly, and principal is due on demand. The outstanding principal balance plus all accrued but unpaid interest shall be due on demand (the “Maturity Date”). Upon default, the interest may be adjusted to the highest rate permissible by law. The Loan is secured by all assets of The B.A.C.K. Center now owned or hereafter acquired. The assets constitute the collateral for the repayment of the Loan. The Loan Agreement also includes covenants, representations, warranties, indemnities and events of default that are customary for facilities of this type. The advance rate is defined as: 60% of eligible accounts receivables. Eligible receivables include all Medicare and Medicaid receivables less than 90 days old multiplied by a factor of 0.25, plus all other receivables less than 90 days old multiplied by a factor of 0.50. As of March 31, 2018, The B.A.C.K. Center had not violated the loan covenants. The obligations of The B.A.C.K Center under the Loan Agreement are guaranteed by the shareholders of The B.A.C.K. Center. The Loan Agreement is also guaranteed in the amount of $950,000 by related parties of The B.A.C.K. Center. As of March 31, 2018, and December 31, 2017, the outstanding balance on the Loan was $440,024.

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 5— NOTES PAYABLE Notes payable as of March 31, 2018 and 2017 are comprised of the following: March 31. 2018 December 31. 2017 Note Payable, GE Arm $ 5,063 $ 12,536 Capital Leases- Equipment 193,740 77,162 198,803 89,698 Less current portion (49,515 ) (29,552 ) Long term portion $ 149,288 $ 60,146 Note payable — equipment financing On February 25, 2013, the Company accepted the delivery of C-arm equipment under the equipment finance lease. As such, the component price accepted of $124,797 is due over 63 months and the associated monthly payment is $0 for the first three months and $2,388 for the remaining 60 months, including interest at 7.39% per annum. Capital leases — equipment On February 6, 2017, the Company entered into a capital lease agreement to acquire equipment with 48 monthly payments of $611 payable through January 6, 2021 with an effective interest rate of 14.561% per annum. The Company may elect to acquire the leased equipment at a nominal amount at the end of the lease. In June 2017, the Company entered into a lease agreement to acquire equipment with 60 monthly payments of $1,223 payable through June 2021 with an effective interest rate of 5.00% per annum. The Company may elect to acquire the leased equipment at a nominal amount at the end of the lease. On January 29, 2018 the Company entered into a lease agreement to acquire equipment with 60 monthly payments of $1,925 payable through December 2018 with an effective interest rate of 10.2% per annum. The Company may elect to acquire the leased equipment at a nominal amount at the end of the lease. Aggregate principal maturities of long-term debt as of March 31, 2018 Amount Year ended December 31, 2018 $ 29,763 Year ended December 31, 2019 35,602 Year ended December 31, 2020 38,967 Year ended December 31, 2021 35,555 Year ended December 31, 2022 and beyond 58,916 Total $ 198,803

TEMPORARY EQUITY 2022 PUT OPTIO

TEMPORARY EQUITY 2022 PUT OPTION	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
TEMPORARY EQUITY 2022 PUT OPTION	NOTE 6 — TEMPORARY EQUITY 2022 PUT OPTION On February 6, 2018, the Company and Steward Health Care System LLC (“Steward”) entered into a Stock Purchase Agreement (the “Purchase Agreement”).Pursuant to the terms of the Purchase Agreement, Steward will acquire from the Company 5,000,000 shares of common stock of the Company for cash consideration of $7,500,000. As a result of the transaction, Steward owned 15.5% of all of the issued and outstanding shares of common stock of the Company. The Company has agreed that, upon demand from Steward after the six month anniversary of the Closing Date, the Company shall use its reasonable best efforts to prepare and file with the Securities and Exchange Commission, a registration statement and such other documents as may be necessary in the advice of counsel for the Company, and use its commercially reasonable efforts to have such registration statement declared effective in order to comply with the provisions of the Securities Act of 1933, as amended, so as to permit the registered resale of the common shares. In addition, the Company has agreed that, on or after April 1, 2022, upon ninety (90) days prior written notice, Steward may sell fifty percent (50%) of the common stock to the Company one-time during each of the following two (2) calendar years thereafter at a price equal to the purchase price under the Purchase Agreement pro-rated for the number of shares being purchased. Notwithstanding the foregoing, the put option shall automatically terminate and be of no further force and effect in the event the market capitalization (as defined in the Purchase Agreement) of the Company is equal to or more than $100,000,000 at any time after the date of the Purchase Agreement. Due to the nature of the put agreement as described above, the Company has classified to temporary equity the net proceeds from the sale of the Company’s common stock.

CAPITAL STOCK

CAPITAL STOCK	3 Months Ended
	Mar. 31, 2018
Stockholders' Equity Note [Abstract]
CAPITAL STOCK	NOTE 7 — CAPITAL STOCK Common stock During the three months ended March 31, 2018, the Company issued an aggregate of 9,571 shares of its common stock to a service provider at an aggregate fair value of $13,575. During the three months ended March 31, 2018 the Company returned to authorized and cancelled 189,020 previously acquired common stock treasury shares with a carrying value of $249,265. During the three months ended March 31, 2018, the Company cancelled a net of 5,000 shares of common stock previously issued to a service provider.

STOCK OPTIONS, WARRANTS AND RES

STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS	NOTE 8 — STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS Options The following table presents information related to stock options at March 31, 2018: Options Outstanding Exercise Price Number of Options Weighted Average Remaining Life in Years Exercisable Number of Options $ 1.35 3,000,000 5.75 — Transactions involving stock options issued are summarized as follows: Number of Shares Weighted Average Price Per Share Outstanding at December 31, 2017: 3,000,000 1.35 Granted — — Exercised — — Expired — — Outstanding at March 31, 2018 3,000,000 $ 1.35 The aggregate intrinsic value of all outstanding options of $210,000 represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.42 as of March 31, 2018, which would have been received by the option holders had those option holders exercised their options as of that date. Restricted Stock Units (“RSU”) Transactions involving restricted stock units issued are summarized as follows: Restricted share units as of December 31, 2017 921,100 Granted 327,677 Forfeited — Unvested restricted shares as of March 31, 2018 1,248,777 In 2018, the Company granted 327,677 performance-based, restricted stock units vesting over four or five years depending on the grant. The estimated fair value of the granted restricted stock units of $167,000 is being recognized over the vesting periods. As of March 31, 2018, stock-based compensation related to restricted stock awards of $1,056,963 remains unamortized and is expected to be amortized over the weighted average remaining period of 3.46 years. The Company previously issued warrants of 1,875,000 in 2011, since 2011 no additional warrants have been issued and will expire on December 23, 2018. As of March 31, 2018, the aggregate intrinsic value of all warrants was zero.

VARIABLE INTEREST ENTITY

VARIABLE INTEREST ENTITY	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
VARIABLE INTEREST ENTITY	NOTE 9 — VARIABLE INTEREST ENTITY Brevard Orthopaedic Spine & Pain Clinic, Inc. The Company has determined that The B.A.C.K. Center is a VIE . In determining whether the Company has the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIE, the Company evaluates all its economic interests in the entity, regardless of form (debt, equity, management and servicing fees, and other contractual arrangements). This evaluation considers all relevant factors of the entity’s structure, including: the entity’s capital structure, contractual rights to earnings (losses), subordination of our interests relative to those of other investors, contingent payments, as well as other contractual arrangements that have potential to be economically significant. The evaluation of each of these factors in reaching a conclusion about the potential significance of the Company’s economic interests is a matter that requires the exercise of professional judgment. The assets of The B.A.C.K. Center can only be used to settle obligations of the VIE, additionally, creditors of The B.A.C.K. Center do not have recourse against the general credit of the primary beneficiary. The tables below summarize the assets and liabilities associated with The B.A.C.K. Center as of March 31, 2018 and December 31, 2017: March 31, 2018 December 31, 2017 Current assets: Cash $ 478,740 $ 238,402 Accounts receivable, net 4,129,865 3,526,789 Other current assets 725,957 765,236 Total current assets 5,334,562 4,530,427 Property and equipment, net 209,950 73,791 Other assets 22,005 22,005 Total assets $ 5,566,517 $ 4,626,223 Current liabilities: Accounts payable and accrued liabilities $ 854,018 $ 628,304 Due to First Choice Healthcare Solutions, Inc. 2,287,502 1,700,210 Other current liabilities 492,141 485,432 Total current liabilities 3,633,661 2,813,946 Long term debt 2,071,542 1,950,963 Total liabilities 5,705,203 4,764,909 Non-controlling interest (138,686 ) (138,686 ) Total liabilities and deficit $ 5,566,517 $ 4,626,223 Total revenues from The B.A.C.K. Center were $3,974,593 for the three months ended March 31, 2018. Related expenses consisted primarily of salaries and benefits of $1,776,997, other operating expense of $938,794, general and administrative expenses of $618,337 depreciation of $10,190, interest and financing costs of $4,810; and other income of $38,553 for the three months ended March 31, 2018. (See Note 11 – Segment Reporting) Total revenues from The B.A.C.K. Center were $3,430,655 for the three months ended March 31, 2017. Related expenses consisted primarily of salaries and benefits of $1,718,717, operating expenses of $856,482, general and administrative expenses of $638,798, depreciation of $6,162, interest and financing costs of $3,904; and other income of $45,684 for the three months ended March 31, 2017. (See Note 11 – Segment Reporting) Crane Creek Surgery Center In 2015, the Company had determined that Crane Creek is a VIE . This evaluation requires consideration of all facts and circumstances relevant to decision-making that affects the entity’s future performance and the exercise of professional judgment in deciding which decision-making rights are most important. In determining whether the Company has the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIE, the Company evaluates all its economic interests in the entity, regardless of form (debt, equity, management and servicing fees, and other contractual arrangements). This evaluation considers all relevant factors of the entity’s structure, including: the entity’s capital structure, contractual rights to earnings (losses), subordination of our interests relative to those of other investors, contingent payments, as well as other contractual arrangements that have potential to be economically significant. The evaluation of each of these factors in reaching a conclusion about the potential significance of the Company’s economic interests is a matter that requires the exercise of professional judgment. The assets of Crane Creek can only be used to settle obligations of the VIE, additionally, creditors of the Crane Creek do not have recourse against the general credit of the primary beneficiary. On January 31, 2018 effective January 1, 2018), the Company entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with HMA Blue Chip Investments, LLC (“Blue Chip”).Pursuant to the terms of the Purchase Agreement, the Company acquired from Blue Chip 24.05 Class B Units of membership interest in the Center for cash consideration of $400,000 (the “Transaction”), representing a 25% ownership interest in the Center. As a result of the Transaction, the Company held a 65% ownership interest in the Center. Termination and Assignment Agreement On January 31, 2018 (effective January 1. 2018), the Company entered into a Termination and Assignment Agreement (the “Termination Agreement”) with Crane Creek Surgical Partners, LLC (the “Center”) and BCS-Management, LLC (“BCS”). Pursuant to the terms of the Termination Agreement, the Center and BCS will terminate their respective rights and obligations under that certain Amended and Restated Management Services Agreement dated as of September 1, 2013 (the “Management Agreement”). Each of the Center and BCS has agreed to release the other and certain other persons from any and all claims arising out of or relating to the Management Agreement, except for claims arising out of the Termination Agreement and claims made by third parties against either party. In addition, pursuant to the terms of the Termination Agreement, BCS will assign, grant, convey and transfer to the Company all of BCS’s right, title and interest in and to the Management Agreement, including but not limited to the right to accept management fees as set forth in the Management Agreement, and the Company will assume all of BCS’s duties and obligations under the Management Agreement. Until March 31, 2018, BCS will provide the Center business office, financial, accounting and other related services necessary to assist the transition of the operation of the Center to the Company. As a result of the Purchase agreement described above, Crane Creek Surgical Partners, LLC became a majority-owned subsidiary of the Company effective January 1, 2018. The tables below summarize the assets and liabilities associated with the Crane Creek as of December 31, 2017 (as a VIE): December 31. 2017 Current assets: Cash $ 464,074 Accounts receivable, net 893,817 Other current assets 151,040 Total current assets 1,508,931 Property and equipment, net 396,136 Goodwill 899,465 Total assets $ 2,804,532 Current liabilities: Accounts payable and accrued liabilities $ 852,208 Capital leases, short term 12,001 Other current liabilities 251,588 Total current liabilities 1,115,797 Capital leases, long term 47,049 Deferred rent 559,239 Total liabilities 1,722,085 Equity-First Choice Healthcare Solutions, Inc. 432,979 Non-controlling interest 649,468 Total liabilities and deficit $ 2,804,532 Total revenues from Crane Creek were $1,190,425 for the three months ended March 31, 2017. Related expenses consisted primarily of salaries and benefits of $298,299, surgical supplies and operating expenses of $852,122, general and administrative expenses of $136,354, depreciation of $28,149, interest expense of $866 and miscellaneous income of $3,668 for the three months ended March 31, 2017. (See Note 11 – Segment Reporting)

NON-CONTROLLING INTEREST

NON-CONTROLLING INTEREST	3 Months Ended
	Mar. 31, 2018
Noncontrolling Interest [Abstract]
NON-CONTROLLING INTEREST	NOTE 10 — NON-CONTROLLING INTEREST A reconciliation of The B.A.C.K. Center non-controlling income attributable to the Company: Net loss attributable to non-controlling interest for the three months ended March 31, 2018: Net income $ 587,292 Average Non-controlling interest percentage of profit/losses -0- % Net income attributable to the non-controlling interest $ -0- Net income attributable to non-controlling interest for the three months ended March 31, 2017: Net income $ 170,872 Average Non-controlling interest percentage of profit/losses -0- % Net income attributable to the non-controlling interest $ -0- The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2018: Balance, December 31, 2017 $ (138,686 ) Transfer (to) from the non-controlling interest as a result of change in ownership -- Net income attributable to the non-controlling interest -- Balance, March 31, 2018 $ (138,686 ) A reconciliation of the Crane Creek non-controlling income attributable to the Company: Net income attributable to the non-controlling interest for the three months ended March 31, 2018: Net income $ 15,858 Average Non-controlling interest percentage of profit/losses 35 % Net income/loss attributable to the non-controlling interest $ 5,550 Net income attributable to non-controlling interest for the three months ended March 31, 2017: Net loss $ (121,698 ) Average Non-controlling interest percentage of profit/losses 60 % Net income/loss attributable to the non-controlling interest $ (73,018 ) The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2018 Balance, December 31, 2017 $ 649,468 Transfer (to) from the non-controlling interest as a result of change in ownership (270,611 ) Net income attributable to the non-controlling interest 5,550 Balance, March 31, 2018 $ 384,407 Effective January 1, 2018, the Company acquired a 25% interest in Crane Creek for a purchase price of $400,000. The excess payment of $129,389 over book value of $270,611 was adjusted to the Company’s additional paid in capital.

SEGMENT REPORTING

SEGMENT REPORTING	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 11 — SEGMENT REPORTING The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has three reportable segments: FCID Medical, Inc., The B.A.C.K. Center and CCSC Holdings, Inc. (“CCSC”). All reportable segments derive revenue for medical services provided to patients; and The B.A.C.K Center additionally derives revenue for subleasing space within its building and medical services provided to patients. With the aforementioned sale and leaseback of Marina Towers on March 31, 2016, the Company will no longer report segmented rental revenue received from third-party Marina Tower tenants under the segment heading “Marina Towers.” Rather, the Company has consolidated rental revenue received from third-party tenants of Marina Towers under the “Corporate” segment for both the 2017 and 2016 comparable reporting periods; and will continue to do so hereafter. Information concerning the operations of the Company’s reportable segments is as follows: Summary Statement of Operations for the three months ended March 31, 2018: FCID Brevard Medical Orthopaedic CCSC Corporate Total Revenue: Net Patient Service Revenue $ 3,363,648 $ 3,634,091 $ 1,205,370 $ — $ — $ 8,203,110 Rental revenue — 340,502 430,144 (187,859 ) 582,787 Total Revenue 3,363,648 3,974,593 1,205,370 430,144 (187,859 ) 8,785,897 Operating expenses: Salaries & benefits 1,928,803 1,776,997 266,466 357,020 4,329,285 Other operating expenses 677,250 938,794 786,519 404,369 (174,145 ) 2,632,786 General and administrative 265,428 618,337 71,185 412,599 (13,714 ) 1,353,836 Depreciation and amortization 80,051 10,190 26,004 85,667 — 201,912 Total operating expenses 2,951,532 3,344,318 1,150,174 1,259,655 (187,859 ) 8,517,819 Net income (loss) from operations: 412,116 630,275 55,196 (829,511 ) — 268,078 Interest income (expense) (17,313 ) (4,810 ) (1,481 ) 93 — (23,512 ) Other income (expense) — 38,553 1,019 750 — 40,322 Net Income (Loss) before income taxes: 394,803 664,018 54,734 (828,668 ) — 284,888 Income taxes — — — — — — Net income (Loss) 394,803 664,018 54,734 (828,668 ) — 284,888 Non-controlling interest — — (5,550 ) — — (5,550 ) Net income (loss) attributable to First Choice Healthcare Solutions $ 394,803 $ 664,018 $ 49,184 $ (828,668 ) $ — $ 279,338 Summary Statement of Operations for the three months ended March 31, 2017: FCID Brevard Intercompany Medical Orthopaedic CCSC Corporate Eliminations Total Revenue: Net Patient Service Revenue $ 2,860,986 $ 3,090,579 $ 1,190,425 $ — $ — $ 7,141,990 Rental revenue — 340,076 431,850 (193,563 ) 578,363 Total Revenue 2,860,986 3,430,655 1,190,425 431,850 (193,563 ) 7,720,353 Operating expenses: Salaries & benefits 1,460,235 1,718,717 298,299 239,124 — 3,716,375 Other operating expenses 591,151 856,482 852,122 408,861 (179,433 ) 2,529,183 General and administrative 160,310 638,798 136,354 252,502 (14,130 ) 1,173,834 Depreciation and amortization 69,741 6,162 28,149 85,436 — 189,488 Total operating expenses 2,281,437 3,220,159 1,314,924 985,923 (193,563 ) 7,608,880 Net income (loss) from operations: 579,549 210,496 (124,499 ) (554,073 ) — 111,473 Interest income (expense) (27,558 ) (3,904 ) (866 ) 254 — (32,074 ) Other income (expense) — 45,684 3,668 750 — 50,102 Net Income before income taxes: 551,991 252,276 (121,697 ) (553,069 ) — 129,501 Income taxes — — — — Net income 551,991 252,276 (121,697 ) (553,069 ) — 129,501 Non controlling interest — — 73,018 — — 73,018 Net income attributable to First Choice Healthcare Solutions $ 551,991 $ 252,276 $ (48,679 ) $ (553,069 ) $ — $ 202,519

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS On April 23, 2018 the Company signed a four year operating lease for approximately $700,000 of equipment for the Company’s CCSC division. The lease requires 16 quarterly payments of $49,230.

SIGNIFICANT ACCOUNTING POLICI19

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Use of estimates	Use of estimates The preparation of the financial statements in conformity with United States generally accepted accounting principles (“U. S. GAAP”) requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates include the recoverability and useful lives of long-lived assets, provision against bad debt, the fair value of the Company’s stock, and stock-based compensation. Actual results may differ from these estimates.
Revenue recognition	Revenue recognition The Company recognizes revenue when: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company recognizes, significant patient service revenue at the time the services are rendered, even though it does not assess the patient’s ability to pay. Therefore, The Company’s interim and annual periods reports disclose both, its policy for assessing and disclosing the timing and amount of uncollectable patient service revenue recognized as doubtful. Qualitative and quantitative information about significant changes in the allowance for doubtful accounts related to patient accounts receivable are disclosed in the Company’s reports. These estimates are based upon the history and identified trends for each of our payers.
Patient fee revenue	Patient fee revenue Patient fee revenue, net of contractual allowance and discounts, consists of net patient fees received from insurance companies, third party payors (including federal and state agencies), hospitals and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments and discounts. Patient fee revenue is recorded in the period in which the services are provided
Rental Revenue	Rental Revenue In addition to housing our corporate headquarters and First Choice Medical Group, the building leases 38,334 square feet of commercial office space to non-affiliated tenants. Our corporate headquarters and FCID Holdings offices currently utilize 4,274 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 21,902 square feet on the ground, first and second floors.
Concentrations of credit risk	Concentrations of credit risk The Company’s financial instruments that are exposed to a concentration of customer risk and accounts receivable risk. Occasionally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. Revenues and accounts receivable are concentrated between two major payers with the approximate risk level outlined below. Concentration of Risk Revenue Concentration: Three months ended March 31, 2018 2017 Medicare 36.0 % 35.5 % Commercial Payor 1 15.9 % 19.0 % Commercial Payor 2 — 11.0 % Receivable Concentration: March 31, March 31, 2018 2017 Medicare 24.6 % 22.9 % Commercial Payor 1 11.6 % 17.4 % Commercial Payor 2 11.9 % 11.7 %
Accounts receivables	Accounts receivables Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the allowance for doubtful accounts. Patient receivables: Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides an allowance for doubtful accounts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts. Rental receivables: Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful accounts. In the year ended 2017, the Company changed its estimates of the allowance for doubtful accounts related to its customers, primarily based on historical experience of write-offs of outstanding accounts receivable. The result of this change in estimate resulted in an increase compared to the year ended December 31, 2016 to the allowance for doubtful accounts by approximately $3.2 million in the year ended 2017. As of March 31, 2018, and December 31, 2017, the Company’s allowance for doubtful accounts was $7,563,566 and $7,285,004 respectively.
Net (loss) income per share	Net (loss) income per share Basic net (loss) income per common share is based upon the weighted-average number of common shares outstanding. Diluted net income per common share is based on the weighted-average number of common shares outstanding and potentially dilutive common shares outstanding and computed as follows: Three Months ended March 31, 2018 2017 Numerator: Net income attributable to First Choice Healthcare Solutions, Inc. $ 279,338 $ 202,519 Denominator: Weighted-average common shares, basic 28,610,793 26,252,505 Weighted-average common shares, diluted 29,410,793 27,052,505 Basic: $ 0.01 $ 0.01 Diluted: $ 0.01 $ 0.01 Potentially dilutive common shares from convertible debt, options and warrants are determined by applying the treasury stock method to the assumed exercise of warrants and share options are were excluded from the computation of the diluted net income per share because their inclusion would be anti-dilutive. In addition, there were no vested restrict stock for periods presented. Potentially dilutive securities excluded from the basic and diluted net income per share are as follows: March 31, 2018 2017 Warrants to purchase common stock 1,875,000 1,875,000 Options to purchase common stock 3,000,000 3,000,000 Restricted stock awards 1,248,777 660,000 Total 6,123,777 5,535,000
Stock-based compensation	Stock-based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the unaudited condensed consolidated statements of operations, as if such amounts were paid in cash. Upon exercise of a common stock equivalent, the Company issues new shares of common stock out of its authorized shares.
Segment information	Segment information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all the material financial information related to the Company’s principal operating segments. (See Note 11 – Segment Reporting).
Treasury Stock	Treasury Stock The Company uses the cost method when it purchases its own common stock as treasury shares and displays treasury stock as a reduction of shareholders’ equity. As of March 31, 2018 the Company canceled all of its outstanding treasury stock.
Reclassification	Reclassifications Certain reclassifications have been made to prior period’s data to conform to the current year’s presentation. These reclassifications had no impact on reported income.
Litigations, Claims and Assessments	Litigations, Claims and Assessments From time to time, we may become involved in lawsuits and legal proceedings which arise in the ordinary course of business including potential disputes with patients. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our physicians. Currently, we have no pending litigation that is deemed to be material to the consolidated financial statements.
Recent accounting pronouncements	Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers” to supersede previous revenue recognition guidance under current U.S. GAAP. The guidance presents a single five-step model for comprehensive revenue recognition that requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Two options are available for implementation of the standard which is either the retrospective approach or cumulative effect adjustment approach. The guidance becomes effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. The Company adopted ASU 2014-09 using the modified retrospective transition method in the first quarter of 2018 and such adoption did not have a material impact on the condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases except for short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its financial statements and related disclosures. In August 2016, the FASB issued ASU 2016-15—Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2016-15 in the first quarter of 2018 and such adoption did not have a material impact on the Company. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company adopted ASU 2017-01 in the first quarter of 2018 and such adoption did not have a material impact on the Company. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value because of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently reviewing the impact of adoption of ASU 2017-11 on its financial statements.
Subsequent events	Subsequent events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

SIGNIFICANT ACCOUNTING POLICI20

SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2018
Significant Accounting Policies Tables
Concentrations of credit risk	Revenues and accounts receivable are concentrated between two major payers with the approximate risk level outlined below. Concentration of Risk Revenue Concentration: Three months ended March 31, 2018 2017 Medicare 36.0 % 35.5 % Commercial Payor 1 15.9 % 19.0 % Commercial Payor 2 — 11.0 % Receivable Concentration: March 31, March 31, 2018 2017 Medicare 24.6 % 22.9 % Commercial Payor 1 11.6 % 17.4 % Commercial Payor 2 11.9 % 11.7 %
Net (loss) income per share	Diluted net income per common share is based on the weighted-average number of common shares outstanding and potentially dilutive common shares outstanding and computed as follows: Three Months ended March 31, 2018 2017 Numerator: Net income attributable to First Choice Healthcare Solutions, Inc. $ 279,338 $ 202,519 Denominator: Weighted-average common shares, basic 28,610,793 26,252,505 Weighted-average common shares, diluted 29,410,793 27,052,505 Basic: $ 0.01 $ 0.01 Diluted: $ 0.01 $ 0.01 Potentially dilutive securities excluded from the basic and diluted net income per share are as follows: March 31, 2018 2017 Warrants to purchase common stock 1,875,000 1,875,000 Options to purchase common stock 3,000,000 3,000,000 Restricted stock awards 1,248,777 660,000 Total 6,123,777 5,535,000

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Schedule of notes payable	Notes payable as of March 31, 2018 and 2017 are comprised of the following: March 31. 2018 December 31. 2017 Note Payable, GE Arm $ 5,063 $ 12,536 Capital Leases- Equipment 193,740 77,162 198,803 89,698 Less current portion (49,515 ) (29,552 ) Long term portion $ 149,288 $ 60,146
Schedule of aggregate principal maturities of long-term debt	Aggregate principal maturities of long-term debt as of March 31, 2018 Amount Year ended December 31, 2018 $ 29,763 Year ended December 31, 2019 35,602 Year ended December 31, 2020 38,967 Year ended December 31, 2021 35,555 Year ended December 31, 2022 and beyond 58,916 Total $ 198,803

STOCK OPTIONS, WARRANTS AND R22

STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Options Outstanding And Related Exercise Prices	The following table presents information related to stock options at March 31, 2018: Options Outstanding Exercise Price Number of Options Weighted Average Remaining Life in Years Exercisable Number of Options $ 1.35 3,000,000 5.75 —
Schedule of Share-based Compensation, Stock Options, Activity	Transactions involving stock options issued are summarized as follows: Number of Shares Weighted Average Price Per Share Outstanding at December 31, 2017: 3,000,000 1.35 Granted — — Exercised — — Expired — — Outstanding at March 31, 2018 3,000,000 $ 1.35
Schedule of Share-based Compensation, Restricted Stock Units	Transactions involving restricted stock units issued are summarized as follows: Restricted share units as of December 31, 2017 921,100 Granted 327,677 Forfeited — Unvested restricted shares as of March 31, 2018 1,248,777

VARIABLE INTEREST ENTITY (Table

VARIABLE INTEREST ENTITY (Tables)	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Variable Interest Entities	The tables below summarize the assets and liabilities associated with The B.A.C.K. Center as of March 31, 2018 and December 31, 2017: March 31, 2018 December 31, 2017 Current assets: Cash $ 478,740 $ 238,402 Accounts receivable, net 4,129,865 3,526,789 Other current assets 725,957 765,236 Total current assets 5,334,562 4,530,427 Property and equipment, net 209,950 73,791 Other assets 22,005 22,005 Total assets $ 5,566,517 $ 4,626,223 Current liabilities: Accounts payable and accrued liabilities $ 854,018 $ 628,304 Due to First Choice Healthcare Solutions, Inc. 2,287,502 1,700,210 Other current liabilities 492,141 485,432 Total current liabilities 3,633,661 2,813,946 Long term debt 2,071,542 1,950,963 Total liabilities 5,705,203 4,764,909 Non-controlling interest (138,686 ) (138,686 ) Total liabilities and deficit $ 5,566,517 $ 4,626,223 The tables below summarize the assets and liabilities associated with the Crane Creek as of December 31, 2017 (as a VIE): December 31. 2017 Current assets: Cash $ 464,074 Accounts receivable, net 893,817 Other current assets 151,040 Total current assets 1,508,931 Property and equipment, net 396,136 Goodwill 899,465 Total assets $ 2,804,532 Current liabilities: Accounts payable and accrued liabilities $ 852,208 Capital leases, short term 12,001 Other current liabilities 251,588 Total current liabilities 1,115,797 Capital leases, long term 47,049 Deferred rent 559,239 Total liabilities 1,722,085 Equity-First Choice Healthcare Solutions, Inc. 432,979 Non-controlling interest 649,468 Total liabilities and deficit $ 2,804,532

NON-CONTROLLING INTEREST (Table

NON-CONTROLLING INTEREST (Tables)	3 Months Ended
	Mar. 31, 2018
Non-controlling Interest Tables
Schedule of Net loss attributable to non-controlling interest	Net loss attributable to non-controlling interest for the three months ended March 31, 2018: Net income $ 587,292 Average Non-controlling interest percentage of profit/losses -0- % Net income attributable to the non-controlling interest $ -0- Net income attributable to non-controlling interest for the three months ended March 31, 2017: Net income $ 170,872 Average Non-controlling interest percentage of profit/losses -0- % Net income attributable to the non-controlling interest $ -0- The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2018: Balance, December 31, 2017 $ (138,686 ) Transfer (to) from the non-controlling interest as a result of change in ownership -- Net income attributable to the non-controlling interest -- Balance, March 31, 2018 $ (138,686 ) A reconciliation of the Crane Creek non-controlling income attributable to the Company: Net income attributable to the non-controlling interest for the three months ended March 31, 2018: Net income $ 15,858 Average Non-controlling interest percentage of profit/losses 35 % Net income/loss attributable to the non-controlling interest $ 5,550 Net income attributable to non-controlling interest for the three months ended March 31, 2017: Net loss $ (121,698 ) Average Non-controlling interest percentage of profit/losses 60 % Net income/loss attributable to the non-controlling interest $ (73,018 ) The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2018 Balance, December 31, 2017 $ 649,468 Transfer (to) from the non-controlling interest as a result of change in ownership (270,611 ) Net income attributable to the non-controlling interest 5,550 Balance, March 31, 2018 $ 384,407

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Summary Statement of Operations for the three months ended March 31, 2018: FCID Brevard Medical Orthopaedic CCSC Corporate Total Revenue: Net Patient Service Revenue $ 3,363,648 $ 3,634,091 $ 1,205,370 $ — $ — $ 8,203,110 Rental revenue — 340,502 430,144 (187,859 ) 582,787 Total Revenue 3,363,648 3,974,593 1,205,370 430,144 (187,859 ) 8,785,897 Operating expenses: Salaries & benefits 1,928,803 1,776,997 266,466 357,020 4,329,285 Other operating expenses 677,250 938,794 786,519 404,369 (174,145 ) 2,632,786 General and administrative 265,428 618,337 71,185 412,599 (13,714 ) 1,353,836 Depreciation and amortization 80,051 10,190 26,004 85,667 — 201,912 Total operating expenses 2,951,532 3,344,318 1,150,174 1,259,655 (187,859 ) 8,517,819 Net income (loss) from operations: 412,116 630,275 55,196 (829,511 ) — 268,078 Interest income (expense) (17,313 ) (4,810 ) (1,481 ) 93 — (23,512 ) Other income (expense) — 38,553 1,019 750 — 40,322 Net Income (Loss) before income taxes: 394,803 664,018 54,734 (828,668 ) — 284,888 Income taxes — — — — — — Net income (Loss) 394,803 664,018 54,734 (828,668 ) — 284,888 Non-controlling interest — — (5,550 ) — — (5,550 ) Net income (loss) attributable to First Choice Healthcare Solutions $ 394,803 $ 664,018 $ 49,184 $ (828,668 ) $ — $ 279,338 Summary Statement of Operations for the three months ended March 31, 2017: FCID Brevard Intercompany Medical Orthopaedic CCSC Corporate Eliminations Total Revenue: Net Patient Service Revenue $ 2,860,986 $ 3,090,579 $ 1,190,425 $ — $ — $ 7,141,990 Rental revenue — 340,076 431,850 (193,563 ) 578,363 Total Revenue 2,860,986 3,430,655 1,190,425 431,850 (193,563 ) 7,720,353 Operating expenses: Salaries & benefits 1,460,235 1,718,717 298,299 239,124 — 3,716,375 Other operating expenses 591,151 856,482 852,122 408,861 (179,433 ) 2,529,183 General and administrative 160,310 638,798 136,354 252,502 (14,130 ) 1,173,834 Depreciation and amortization 69,741 6,162 28,149 85,436 — 189,488 Total operating expenses 2,281,437 3,220,159 1,314,924 985,923 (193,563 ) 7,608,880 Net income (loss) from operations: 579,549 210,496 (124,499 ) (554,073 ) — 111,473 Interest income (expense) (27,558 ) (3,904 ) (866 ) 254 — (32,074 ) Other income (expense) — 45,684 3,668 750 — 50,102 Net Income before income taxes: 551,991 252,276 (121,697 ) (553,069 ) — 129,501 Income taxes — — — — Net income 551,991 252,276 (121,697 ) (553,069 ) — 129,501 Non controlling interest — — 73,018 — — 73,018 Net income attributable to First Choice Healthcare Solutions $ 551,991 $ 252,276 $ (48,679 ) $ (553,069 ) $ — $ 202,519

SIGNIFICANT ACCOUNTING POLICI26

SIGNIFICANT ACCOUNTING POLICIES (Details)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Sales Revenue, Net [Member] | Medicare
Concentration of Risk Percentage	36.00%	35.50%
Sales Revenue, Net [Member] | Commercial Payor 1
Concentration of Risk Percentage	15.90%	19.00%
Sales Revenue, Net [Member] | Commercial Payor 2
Concentration of Risk Percentage		11.00%
Accounts Receivable [Member] | Medicare
Concentration of Risk Percentage	24.60%	22.90%
Accounts Receivable [Member] | Commercial Payor 1
Concentration of Risk Percentage	11.60%	17.40%
Accounts Receivable [Member] | Commercial Payor 2
Concentration of Risk Percentage	11.90%	11.70%

SIGNIFICANT ACCOUNTING POLICI27

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Numerator:
Net income attributable to First Choice Healthcare Solutions, Inc.	$ 279,338	$ 202,519
Denominator:
Weighted-average common shares, basic	28,610,793	26,252,505
Weighted-average common shares, diluted	29,410,793	27,052,505
Basic:	$ 0.01	$ 0.01
Diluted:	$ 0.01	$ 0.01

SIGNIFICANT ACCOUNTING POLICI28

SIGNIFICANT ACCOUNTING POLICIES (Details 2) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share	6,123,777	5,535,000
Warrants to purchase common stock [Member]
Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share	1,875,000	1,875,000
Options to purchase common stock [Member]
Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share	3,000,000	3,000,000
Restricted stock awards [Member]
Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share	1,248,777	660,000

SIGNIFICANT ACCOUNTING POLICI29

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 31, 2018
Accounting Policies [Abstract]
Increase in allowance for doubtful accounts	$ 3,200,000
Allowance for Doubtful Accounts Receivable	$ 7,285,004	$ 7,563,566

LIQUIDITY (Details Narrative)

LIQUIDITY (Details Narrative)	Mar. 01, 2018USD ($)shares
Liquidity Disclosures [Abstract]
Debt Conversion, Converted Instrument, Amount | $	$ 7,500,000
Debt Conversion, Converted Instrument, Shares Issued | shares	5,000,000

LINES OF CREDIT (Details Narrat

LINES OF CREDIT (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Line of Credit Facility [Line Items]
Line Of Credit Facility, Amount Outstanding	$ 1,400,000
Line of Credit Facility, Average Outstanding Amount	$ 440,024
Line of Credit, Florida Business Bank [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Term	90 days
Line of Credit Facility, Covenant Terms	The advance rate is defined as: 60% of eligible accounts receivables. Eligible receivables include all Medicare and Medicaid receivables less than 90 days old multiplied by a factor of 0.25, plus all other receivables less than 90 days old multiplied by a factor of 0.50.
Line Of Credit Guaranteed Amount	$ 995,000
Line of Credit Facility, Average Outstanding Amount		$ 440,024
Accounts Receivable [Member] | Line of Credit, Florida Business Bank [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate During Period	1.00%
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,383,000
Line of Credit Facility, Interest Rate Description	Interest rate of Prime floating plus 1.0%, as published in The Wall Street Journal
CT Capital LTD [Member]
Line of Credit Facility [Line Items]
Short-term Debt, Maximum Amount Outstanding During Period	$ 2,500,000
Debt Instrument, Convertible, Terms of Conversion Feature	The Lender may convert up to $2,000,000 of the outstanding principal amount or interest on the Loan into common stock of the Company at a conversion price of $0.75 per share.
Debt Instrument, Interest Rate During Period	6.00%
Debt Instrument, Interest Rate, Effective Percentage	9.99%
Line Of Credit Facility, Amount Outstanding	$ 1,100,000	$ 600,000
Matures date	Jun. 30, 2018

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Notes Payable	$ 198,803	$ 89,698
Less: current portion	(49,515)	(29,552)
Notes payable, long term portion	149,288	60,146
Note Payable GE Arm [Member]
Debt Instrument [Line Items]
Notes Payable	5,063	12,536
Capital lease, Equipment [Member]
Debt Instrument [Line Items]
Notes Payable	$ 193,740	$ 77,162

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1)	Mar. 31, 2018USD ($)
Aggregate maturities of long-term debt:
Year ended December 31, 2018	$ 29,763
Year ended December 31, 2019	35,602
Year ended December 31, 2020	38,967
Year ended December 31, 2021	35,555
Year ended December 31, 2022 and beyond	58,916
Total	$ 198,803

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	Feb. 11, 2017	Jan. 29, 2018	Jun. 30, 2017	Feb. 25, 2018	Feb. 25, 2013
Equipment Capital Lease [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	14.561%	10.20%	5.00%
Debt Instrument, Periodic Payment	$ 611	$ 1,925	$ 1,223
Debt Instrument, Maturity Date	Jan. 6, 2021	Dec. 31, 2018	Jun. 30, 2021
Capital Lease Equipment, Lease Term	48 months	60 months	60 months
C-Arm Equipment [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period				7.39%
Capital Lease Obligations					$ 124,797
Capital Lease Obligations Due In First 3 Months					0
Capital Lease Obligations Due For Remaining Months					$ 2,388
Debt Instrument, Term				60 months

TEMPORARY EQUITY 2022 PUT OPT35

TEMPORARY EQUITY 2022 PUT OPTION (Details Narrattive)	Feb. 06, 2018USD ($)shares
Notes to Financial Statements
Common stock issued for cash consideration, Shares | shares	5,000,000
Common stock issued for cash consideration, Amount | $	$ 7,500,000
Transaction Percentage	15.50%
Temporary equity Description	In addition, , the Company has agreed that, on or after April 1, 2022, upon ninety (90) days prior written notice, Steward may sell fifty percent (50%) of the common stock to the Company one-time during each of the following two (2) calendar years thereafter at a price equal to the purchase price under the Purchase Agreement pro-rated for the number of shares being purchased. Notwithstanding the foregoing, the put option shall automatically terminate and be of no further force and effect in the event the market capitalization (as defined in the Purchase Agreement) of the Company is equal to or more than $100,000,000 at any time after the date of the Purchase Agreement.

CAPITAL STOCK (Details Narrativ

CAPITAL STOCK (Details Narrative)	3 Months Ended
	Mar. 31, 2018USD ($)shares
Capital Stock Details Narrative
Common Stock, Shares, Issued for Services	9,571
Common Stock, Shares, Issued for Services Amount | $	$ 13,575
Common stock previously authorized and returned to treasury, Amount | $	$ 249,265
Common stock previously uthorized and returned to treasury, Shares	189,020
Common stock canceled shares	5,000

STOCK OPTIONS, WARRANTS AND R37

STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details) - $ / shares	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Exercise Price	$ 1.35
Number of options outstanding	3,000,000	3,000,000
Weighted Average Remaining Life in Years	5 years 9 months
Exercisable number of options

STOCK OPTIONS, WARRANTS AND R38

STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details 1)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares, Outstanding | shares	3,000,000
Number of Shares, Granted | shares
Number of Shares, Exercised | shares
Number of Shares, Expired | shares
Number of Shares, Outstanding | shares	3,000,000
Weighted Average Price Per Share, Outstanding | $ / shares	$ 1.35
Weighted Average Price Per Share, Granted | $ / shares
Weighted Average Price Per Share, Exercised | $ / shares
Weighted Average Price Per Share, Expired | $ / shares
Weighted Average Price Per Share, Outstanding | $ / shares	$ 1.35

STOCK OPTIONS, WARRANTS AND R39

STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details 2)	3 Months Ended
	Mar. 31, 2018shares
Number of Shares, Granted
Restricted Stock Units (RSUs) [Member]
Number of restricted share units , Outstanding	921,100
Number of Shares, Granted	327,677
Number of Shares, Forfeited
Unvested restricted shares at end	1,248,777

STOCK OPTIONS, WARRANTS AND R40

STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2011
Aggregate intrinsic value of outstanding options	$ 210,000
Stock Price	$ 1.42
Number of Shares, Granted
Number of warrants isued		1,875,000
Warrant expire term	Dec. 23, 2018
Aggregate intrinsic value of warrants	$ 0
Fair value restricted stock vesting	167,000
Stock based compensation related to restricted stock	$ 1,056,963
Weighted average remaining period	3 years 5 months 16 days
Restricted Stock Units (RSUs) [Member]
Number of Shares, Granted	327,677
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Vesting Period	4 years
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Vesting Period	5 years

VARIABLE INTEREST ENTITY (Detai

VARIABLE INTEREST ENTITY (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 8,474,437	$ 2,015,534	$ 3,901,489	$ 4,593,638
Accounts receivable, net	9,908,563	8,699,714
Total current assets	20,281,772	12,547,288
Property and equipment, net	2,519,638	2,295,163
Other assets	3,824,483	3,908,781
Total assets	26,625,893	18,751,232
Current liabilities:
Accounts payable and accrued liabilities	2,545,295	2,379,404
Total current liabilities	3,642,426	3,474,245
Deferred rent	2,641,579	2,589,568
Total liabilities	7,575,223	7,265,889
Equity-First Choice Healthcare Solutions, Inc	32,172	27,357
Non-controlling interest	245,721	510,782
Total liabilities and deficit	26,625,893	18,751,232
B.A.C.K. Center [Member]
Current assets:
Cash	478,740	238,402
Accounts receivable, net	4,129,865	3,526,789
Other current assets	725,957	765,236
Total current assets	5,334,562	4,530,427
Property and equipment, net	209,950	73,791
Other assets	22,005	22,005
Total assets	5,566,517	4,626,223
Current liabilities:
Accounts payable and accrued liabilities	854,018	628,304
Due to First Choice Healthcare Solutions, Inc.	2,287,502	1,700,210
Other current liabilities	492,141	485,432
Total current liabilities	3,633,661	2,813,946
Long term debt	2,071,542	1,950,963
Total liabilities	5,705,203	4,764,909
Non-controlling interest	(138,686)	(138,686)
Total liabilities and deficit	$ 5,566,517	4,626,223
Crane Creek Surgery Center [Member]
Current assets:
Cash		464,074
Accounts receivable, net		893,817
Other current assets		151,040
Total current assets		1,508,931
Property and equipment, net		396,136
Goodwill		899,465
Total assets		2,804,532
Current liabilities:
Accounts payable and accrued liabilities		852,208
Capital leases, short term		12,001
Other current liabilities		251,588
Total current liabilities		1,115,797
Capital leases, long term		47,049
Deferred rent		559,239
Total liabilities		1,722,085
Equity-First Choice Healthcare Solutions, Inc		432,979
Non-controlling interest		649,468
Total liabilities and deficit		$ 2,804,532

VARIABLE INTEREST ENTITY (Det42

VARIABLE INTEREST ENTITY (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2018	Mar. 31, 2018	Mar. 31, 2017
Total revenues		$ 8,785,897	$ 7,720,353
Salaries and benefits		4,329,285	3,716,375
Other operating expenses		2,632,786	2,529,183
Operating expenses		8,517,819	7,608,880
General and administrative expenses		1,353,836	1,173,834
Interest and financing costs		(23,512)	(32,074)
Other income (expense)		40,322	50,102
B.A.C.K. Center [Member]
Total revenues		3,974,593	3,430,655
Salaries and benefits		1,776,997	1,718,717
Other operating expenses		938,794
Operating expenses			856,482
General and administrative expenses		618,337	638,798
Depreciation		10,190	6,162
Interest and financing costs		38,553	3,904
Other income (expense)		37,731	$ 45,684
Crane Creek Surgery Center [Member]
Total revenues		1,190,425
Salaries and benefits		298,299
Operating expenses		852,122
General and administrative expenses		136,354
Depreciation		28,149
Interest expense		866
Miscellaneous income		$ 3,668
Voting Rights, Description	Pursuant to the terms of the Purchase Agreement, the Company acquired from Blue Chip 24.05 Class B Units of membership interest in the Center for cash consideration of $400,000 (the “Transaction”), representing a 25% ownership interest in the Center. As a result of the Transaction, the Company held a 65% ownership interest in the Center.

NON-CONTROLLING INTEREST (Detai

NON-CONTROLLING INTEREST (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Net income loss attributable to the non-controlling interest	$ (5,550)	$ 73,018
B.A.C.K. Center [Member]
Net income	$ 587,292	$ 170,872
Average Non-controlling interest percentage of profit/losses	0.00%	0.00%
Net income loss attributable to the non-controlling interest		$ 0
CCSC HoldingsInc [Member]
Net income	$ 15,858	$ (121,698)
Average Non-controlling interest percentage of profit/losses	35.00%	60.00%
Net income loss attributable to the non-controlling interest	$ 5,550	$ (73,018)

NON-CONTROLLING INTEREST (Det44

NON-CONTROLLING INTEREST (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Balance at beginning	$ 510,782
Net income loss attributable to the non-controlling interest	(5,550)	$ 73,018
Balance at end	245,721
B.A.C.K. Center [Member]
Balance at beginning	(138,686)
Transfer (to) from the non-controlling interest as a result of change in ownership
Net income loss attributable to the non-controlling interest		0
Balance at end	(138,686)
CCSC HoldingsInc [Member]
Balance at beginning	649,468
Transfer (to) from the non-controlling interest as a result of change in ownership	(270,611)
Net income loss attributable to the non-controlling interest	5,550	$ (73,018)
Balance at end	$ 384,407

NON-CONTROLLING INTEREST (Det45

NON-CONTROLLING INTEREST (Details Narrative) - Crane Creek Surgery Center [Member]	3 Months Ended
	Mar. 31, 2018USD ($)
Bearing interest rate	25.00%
Stock Purchase Price	$ 400,000
Non-controlling interest, Description	The excess payment of $129,389 over book value of $270,611 was adjusted to the Company’s additional paid in capital.

SEGMENT REPORTING (Details)

SEGMENT REPORTING (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue:
Net patient service revenue	$ 8,203,110	$ 7,141,990
Rental revenue	582,787	578,363
Total revenue	8,785,897	7,720,353
Operating expenses:
Salaries & benefits	4,329,285	3,716,375
Other operating expenses	2,632,786	2,529,183
General and administrative	1,353,836	1,173,834
Depreciation and amortization	201,912	189,488
Total operating expenses	8,517,819	7,608,880
Net income (loss) from operations:	268,078	111,473
Interest income (expense)	(23,512)	(32,074)
Other income (expense)	40,322	50,102
Net Income (loss) before income taxes:	284,888	129,501
Income taxes
Net income (loss)	284,888	129,501
Non-controlling interest	(5,550)	73,018
Net income (loss) attributable to First Choice Healthcare Solutions	279,338	202,519
FCID Medical [Member]
Revenue:
Net patient service revenue	3,363,648	2,860,986
Rental revenue
Total revenue	3,363,648	2,860,986
Operating expenses:
Salaries & benefits	1,928,803	1,460,235
Other operating expenses	677,250	591,151
General and administrative	265,428	160,310
Depreciation and amortization	80,051	69,741
Total operating expenses	2,951,532	2,281,437
Net income (loss) from operations:	412,116	579,549
Interest income (expense)	(17,313)	(27,558)
Other income (expense)
Net Income (loss) before income taxes:	394,803	551,991
Income taxes
Net income (loss)	394,803	551,991
Non-controlling interest
Net income (loss) attributable to First Choice Healthcare Solutions	394,803	551,991
Brevard Orthopaedic [Member]
Revenue:
Net patient service revenue	3,634,091	3,090,579
Rental revenue	340,502	340,076
Total revenue	3,974,593	3,430,655
Operating expenses:
Salaries & benefits	1,776,997	1,718,717
Other operating expenses	938,794	856,482
General and administrative	618,337	638,798
Depreciation and amortization	10,190	6,162
Total operating expenses	3,344,318	3,220,159
Net income (loss) from operations:	630,275	210,496
Interest income (expense)	(4,810)	(3,904)
Other income (expense)	38,553	45,684
Net Income (loss) before income taxes:	664,018	252,276
Income taxes
Net income (loss)	664,018	252,276
Non-controlling interest
Net income (loss) attributable to First Choice Healthcare Solutions	664,018	252,276
CCSC [Member]
Revenue:
Net patient service revenue	1,205,370
Total revenue	1,205,370
Operating expenses:
Salaries & benefits	266,466
Other operating expenses	786,519
General and administrative	71,185
Depreciation and amortization	26,004
Total operating expenses	1,150,174
Net income (loss) from operations:	55,196
Interest income (expense)	(1,481)
Other income (expense)	1,019
Net Income (loss) before income taxes:	54,734
Income taxes
Net income (loss)	54,734
Non-controlling interest	(5,550)
Net income (loss) attributable to First Choice Healthcare Solutions	49,184
Corporate [Member]
Revenue:
Net patient service revenue
Rental revenue	430,144	431,850
Total revenue	430,144	431,850
Operating expenses:
Salaries & benefits	357,020	239,124
Other operating expenses	404,369	408,861
General and administrative	412,599	252,502
Depreciation and amortization	85,667	85,436
Total operating expenses	1,259,655	985,923
Net income (loss) from operations:	(829,511)	(554,073)
Interest income (expense)	93	254
Other income (expense)	750	750
Net Income (loss) before income taxes:	(828,668)	(553,069)
Income taxes
Net income (loss)	(828,668)	(553,069)
Non-controlling interest
Net income (loss) attributable to First Choice Healthcare Solutions	(828,668)	(553,069)
Intercompany Elimination [Member]
Revenue:
Net patient service revenue
Rental revenue	(187,859)	(193,563)
Total revenue	(187,859)	(193,563)
Operating expenses:
Salaries & benefits
Other operating expenses	(174,145)	(179,433)
General and administrative	(13,714)	(14,130)
Depreciation and amortization
Total operating expenses	(187,859)	(193,563)
Net income (loss) from operations:
Interest income (expense)
Other income (expense)
Net Income (loss) before income taxes:
Income taxes
Net income (loss)
Non-controlling interest
Net income (loss) attributable to First Choice Healthcare Solutions
The Crane Center [Member]
Revenue:
Net patient service revenue		1,190,425
Total revenue		1,190,425
Operating expenses:
Salaries & benefits		298,299
Other operating expenses		852,122
General and administrative		136,354
Depreciation and amortization		28,149
Total operating expenses		1,314,924
Net income (loss) from operations:		(124,499)
Interest income (expense)		(866)
Other income (expense)		3,668
Net Income (loss) before income taxes:		(121,697)
Net income (loss)		(121,697)
Non-controlling interest		73,018
Net income (loss) attributable to First Choice Healthcare Solutions		$ (48,679)

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]	1 Months Ended
	Apr. 23, 2018USD ($)
Debt Instrument, Periodic Payment	$ 49,230
Capital Lease Obligations	$ 700,000